Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > April 28, 2021, VOTE @ the Meeting ℹNO SHARE SPLIT
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(58)
•••
Comment by whisky11on Apr 22, 2021 10:19am
122 Views
Post# 33044138

RE:RE:RE:RE:RE:RE:RE:April 28, 2021, VOTE @ the Meeting ℹNO SHARE SPLIT

RE:RE:RE:RE:RE:RE:RE:April 28, 2021, VOTE @ the Meeting ℹNO SHARE SPLITBigginvestor]
AngelaL wrote: What do you believe is the reason that the sp has not risen strongly after the recent solid PR's announcing the PAH in-licensing and the start of the Phase 1 trial?


reason I think they might be a buy out or RS coming

whisky11: first of all, stock price rarely goes up on the news. most of the time the rumours are  more powerful. Saying that I have to admit I sleep better and will invest more thanks to last NR.
Second thing Press releases on the company's website are for the people invested already.
R-107 is very important for the humanity, similar to first antibiotics or oxygen and water on Mars.
So we get it, but we need more people to get to know it. Time frame from today to market for
R-107 is far away for  retail investors. Financial involvement of some big-name or government would help.

PS. Reverse split it's cosmetic thing, makes sense when company have specific group of investors on the horizon, wanted to join/ invest in the company, Second thing would be desire to be listed on NASDAQ.
But then If the company is weak NASDAQ will finish it, investors on NASDAQ have a lawyers lots of them I'm sure you heard about the class action lawsuit.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities